Addressing CMV in Solid Organ Transplant Patients with CMV inSIGHT T Cell Immunity

These knowledgeable physicians share how they manage their solid organ transplant patients at risk for CMV by utilizing CMV inSIGHT™ T Cell immunity. These unique case studies will cover situations like neutropenia, low-level CMV, the importance of CD4 T Cells and more. Learn when they use CMV inSIGHT T Cell Immunity testing to evaluate CMV-specific cell mediated immunity, what they do with the information from the lab report, and the outcomes of their patients. Including a recording of the Live Q&A at the end of the original presentation.

In this webinar you will learn how the physicians utilize CMV inSIGHT in the following solid organ transplant cases:

  • Neutropenic patient
  • Low-level CMV DNAemia
  • Importance of CD4 T Cell Response
  • In instances of CMV Resistance
  • When belatacept is used for immunosuppression

Case Studies Presented By:

Justin Rosenheck, DO
Assistant Professor of Internal Medicine at Ohio State University

Dr Kapil Kumar Saharia, MD, MPH
Chief, Solid Organ Transplant Infectious Disease at University of Maryland School of Medicine

Dr. Abhay Dhand, MD, FIDSA
Director of Transplant Infectious Disease at Westchester Medical Center

Guiding Difficult Treatment Decisions for Transplant Recipients

Originally presented as part of the Satellite Symposium at American Transplant Congress (ATC) 2022 
Learn how nephrologists, Dr. Garuav Gupta and Dr. Adnan Khan, utilize inSIGHT testing in Kidney transplant patients

During this excerpt of the panel discussion, speakers present case studies of their utilization of diagnostics to improve patient outcomes in challenging and complicated contexts. They will discuss practical uses of the inSIGHT™ t cell immunity assay, including their application in managing post-transplant patient care.

Presented by: 
Dr. Garuav Gupta
Associate Professor - Division of Nephrology, VCU Medical Center

Dr. Adnan Khan
Assistant Clinical Professor - Medicine (Nephrology), UC San Diego

 

The satellite symposium is sponsored by Eurofins Transplant Diagnostics. It is not part of the ATC official educational program and the sessions and content are not endorsed by ATC.

The use of Cytomegalovirus (CMV) T Cell Immunity Panel to Assess the Risk of Clinically Significant CMV Infection in Recipients of Cellular Therapy with Low Level CMV Viremia

Originally Presented at the 2022 Tandem Meetings of ASBMT and CIBMTR
Learn about an ongoing study which Dr. Chemaly and his team at MD Anderson have utilized CMV inSIGHT™ T Cell Immunity testing to:
  • Identify cellular therapy recipients (both on and off letermovir for prophylaxis) who are high risk for clinically significant CMV infection.
  • Assess the benefit of early treatment of low level CMV viremia who are not on letermovir prophylaxis and high risk for clinically significant CMV infection
  • Determine utility of the CMV inSIGHT™ T Cell Immunity test in the management of low level CMV viremia in high and low risk patient populations on letermovir.

Presented by: 
Dr. Roy Chemaly, MD, MPH, FIDSA, FACP
MD Anderson Cancer Center

Q&A by:
Dr. Fareed Khawaja, MD
MD Anderson Cancer Center

Gain inSIGHT into an Immunocompromised Patient's T Cell Immune Response featuring: CMV and SARS-CoV-2

Originally Presented Virtually at IDWeek in 2021
Join Dr.'s Raval, Khawaja and Kleiboeker to learn more about virus-specific T cell mediated immunity for CMV and SARS-CoV-2. Dr. Raval, a board-certified Cardiologist, will share his experience utilizing the CMV T Cell Immunity panel in heart transplant patients. Dr. Khawaja, an Infectious Disease Physician, will present his experience with CMV cellular immunity in hematopoietic cell transplant recipients with low level viremia. Finally, Dr. Kleiboeker will describe the new SARS-CoV-2 inSIGHT T Cell Immunity test as well as discuss future T Cell Immunity testing innovations to come.

Presented by: 
Dr. Nirav Raval, MD
Advent Health

Dr. Fareed Khawaja, MD
MD Anderson Cancer Center

Dr. Steven Kleiboeker
Eurofins US Clinical Diagnostics

 

Tailoring CMV Prophylaxis Based on a CMV T Cell Immunity Panel Assay in Kidney Transplant Patients

Originally presented Wednesday, December 14th, 2022

This interesting presentation will review The University of Nebraska's Kidney Transplant program's strategy of using CMV inSIGHT T Cell Immunity testing to serially monitor high risk kidney transplant patients to evaluate if prophylaxis could be discontinued early. Dr. Clifford Miles will review data originally presented at the Cutting Edge of Transplantation earlier this year. Dr. Miles is the Medical Director of Kidney and Pancreas Transplant at the University of Nebraska's Medical Center and Associate Professor, Nephrology Division at UNMC's college of medicine. Join us for this special presentation on December 12, 2022. 

Including a special Q&A between authors of the study

Presented By: 

Clifford Miles, MD, FAST,

Associate Professor
Internal Medicine-Nephrology
University of Nebraska Medical Center
Medical Director, Kidney & Pancreas Transplantation, Nebraska Medicine

 

Explore by Category

Chat With An Expert

Back to top